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Introduction {#sec001}
============

Occlusal disharmony is induced by either loss or incorrect positioning of teeth, causing abnormalities in the force or direction of bite. Patients who suffer from occlusal disharmony occasionally complain about stiffness of the neck or shoulders, fatigue, or psychological stress \[[@pone.0236547.ref001]\], suggesting that they may suffer from chronic stress. Indeed, previous cross-sectional studies indicate that occlusal disharmony is associated with difficulties in pronunciation and chewing, unsatisfactory facial aesthetics, and emotional turmoil with low self-esteem, low sociality, and poor oral health-related quality of life in adults \[[@pone.0236547.ref002]\].

Occlusal disharmony in mice, induced by removal of their upper molar teeth, has been shown to elevate plasma corticosteroid level, a marker of stress \[[@pone.0236547.ref003]\]. Further, occlusal disharmony induced by an occlusal cap splint led to urinary cortisol excretion, as well as bruxism (teeth grinding and jaw clenching), which is associated with emotional stress, in monkeys \[[@pone.0236547.ref004],[@pone.0236547.ref005]\]. In addition, an increase of occlusal height induced by cap placement on the incisors resulted in increased levels of serum corticosteroid level and hypothalamic noradrenaline release, together with decreased hippocampal acetylcholine release, in rats \[[@pone.0236547.ref006]--[@pone.0236547.ref008]\]. These findings suggest that occlusal disharmony might cause stress with activation of sympathetic nerve activity and decreased parasympathetic activity, as well as impaired learning and memory. More recently, occlusal disharmony induced by a tooth height increase (0.5 mm) with composite resin in mice was found to be associated with osteoporosis of the lumbar vertebrate and long bones of the hind limb \[[@pone.0236547.ref009]\]. All of these results suggest that improvement of occlusal disharmony may yield sustained gains in health and well-being.

Various forms of stress, such as restraint, electrical footshock, cold stress and psychological stress, such as depression and anxiety, are associated with an increased incidence of cardiovascular disease \[[@pone.0236547.ref010]--[@pone.0236547.ref014]\]. However, the relationship between occlusal disharmony and cardiovascular disease remains poorly understood.

Therefore, the aim of this study was to examine the effects of occlusal disharmony on stress markers, heart rate (HR) control via the autonomic nervous system, systolic cardiac function, histology and signal transduction in the heart, using bite-opening (BO) mice, which have previously been used in research on occlusal disharmony \[[@pone.0236547.ref008],[@pone.0236547.ref009],[@pone.0236547.ref015]\].

Materials and methods {#sec002}
=====================

Mice and experimental protocol {#sec003}
------------------------------

All experiments were performed on male 12-week-old C57BL/6 mice obtained from CLEA Japan (Tokyo, Japan). Occlusal disharmony in mice was induced by introducing a 0.7-mm BO, by cementing a suitable appliance onto the mandibular incisor under anesthesia with medetomidine (0.03 mg/ml), midazolam (0.4 mg/ml), and butorphanol (0.5 mg/ml), injected intraperitoneally \[[@pone.0236547.ref009],[@pone.0236547.ref015],[@pone.0236547.ref016]\] **([Fig 1A](#pone.0236547.g001){ref-type="fig"})**. Mice were group-housed (approximately 3 mice per cage) at 23°C under a 12--12 light/dark cycle with lights on at 8:00 AM and were divided into four groups: a normal control group (Control), a BO-only treatment group (BO), a propranolol-only treatment group (Pro), and a BO plus propranolol treatment group (BO + Pro) **([Fig 1A](#pone.0236547.g001){ref-type="fig"})**. (±)-Propranolol hydrochloride (\#P0884; Sigma, St. Louis MO, USA) was directly dissolved in drinking water (1g/L; freshly prepared every day) \[[@pone.0236547.ref017]\]. Because the BO mice cannot easily eat the standard pellet food (CE-2: 334.9 kcal/100g; CLEA Japan) but can take paste food, the standard pellet food was changed to paste food three days before the BO treatment in all groups, as in previous studies \[[@pone.0236547.ref009],[@pone.0236547.ref015]\]. Body weight (BW), food intake, and water intake were monitored throughout the 2-week experimental period (Control: *n* = 6; BO: *n* = 8; Pro: *n* = 6; BO + Pro: *n* = 10) **([Fig 1B](#pone.0236547.g001){ref-type="fig"} and S1 and S2 Figs of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. All animal experiments complied with the ARRIVE guidelines \[[@pone.0236547.ref018]\] and were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals \[[@pone.0236547.ref019]\] and institutional guidelines. The experimental protocol was approved by the Animal Care and Use Committee of Tsurumi University (No. 29A041).

![Experimental procedure and daily body weight.\
**(A)** Male 12-week-old C57BL/6 mice were divided into four groups: a normal control group (Control), a bite-opening (BO)-treated group, a (±)-propranolol hydrochloride (Pro)-treated group, and a BO plus Pro-treated group (BO + Pro). Propranolol was directly dissolved in drinking water (80 mg/kg/day; freshly prepared every day) for 2 weeks. **(B)** Body weight was measured daily for all animals throughout the 2-week experimental period. \*\**P* \< 0.01 (Control (*n* = 6) vs. BO (*n* = 8)), ^※※^*P* \< 0.01 (Control vs. BO + Pro (*n* = 10)), ^\#\#^*P* \< 0.01 (BO vs. Pro (*n* = 6)), ^‡‡^*P* \< 0.01 (Pro vs. BO + Pro) by two-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **(S1 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.](pone.0236547.g001){#pone.0236547.g001}

Serum corticosterone measurements {#sec004}
---------------------------------

The serum was separated from blood samples collected from the heart of the control (*n* = 5) and BO mice (*n* = 5) under anesthesia at 14 days after the BO treatment. Blood sampling was done in the morning (9:00--10:00AM) and the procedure was completed within 30 s from the time of contact with the mouse \[[@pone.0236547.ref020]\]. The separated serum samples were frozen at -80°C until measurement. The serum corticosterone levels were determined using a Corticosterone HS EIA kit (\#AC-15F1; Immunodiagnostic Systems Ltd., Tyne & Wear, UK), according to the manufacturer's instructions.

Physiological experiments {#sec005}
-------------------------

Mice were anesthetized via a mask with isoflurane (1.0--1.5% v/v) at room temperature to maintain the lightest anesthesia possible and echocardiographic measurements (Control: *n* = 10; BO: *n* = 7; Pro: *n* = 5; BO + Pro: *n* = 7) were performed by means of ultrasonography (TUS-A300, Toshiba, Tokyo, Japan) at 14 days after the BO treatment \[[@pone.0236547.ref021]\]. After the completion of echocardiographic measurement, mice were anesthetized via a mask with isoflurane (1.0--1.5% v/v) at room temperature and killed by cervical dislocation \[[@pone.0236547.ref022],[@pone.0236547.ref023]\]. The heart was excised, rinsed thoroughly in phosphate-buffered saline to eliminate circulating blood in tissue, blotted on filter paper and weighed. The cardiac muscle mass (CMM; mg), the ratio of CMM to tibial length ratio (mm) and the ratio of CMM to BW (g) were used as an indexes of muscle growth. For the immunoblotting analysis, the excised heart tissue was immediately frozen in liquid nitrogen and stored at -80°C until the preparation of crude protein homogenate. For the histologic analysis, the excised heart tissue was immediately frozen in liquid nitrogen with Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA, USA) and stored at -80°C until sectioning.

Electrocardiogram acquisition and analysis {#sec006}
------------------------------------------

Mice were anesthetized with intraperitoneal medetomidine (0.03 mg/ml), midazolam (0.4 mg/ml), and butorphanol (0.5 mg/ml). Then, an abdominal midline incision was made on the ventral surface, and a transmitter (F20-EET; Data Sciences International, St. Paul, MN, USA) was implanted into the mice (*n* = 5) at 14 days before the BO treatment. Electrocardiogram (ECG) signals from the telemetric units in freely moving mice in plastic cages were recorded on an under-cage receiver (Data Sciences International, St. Paul, MN, USA), digitized at a sample rate of 2 kHz, and fed into a microcomputer-based data acquisition system (Power Lab System, AD Instruments, Milford, MA, USA). ECG data were recorded for 24 h at 1 day before the BO treatment to obtain the baseline and at 1, 7 and 14 days after the BO treatment **([Fig 2A](#pone.0236547.g002){ref-type="fig"})** \[[@pone.0236547.ref024],[@pone.0236547.ref025]\]. ECG signals processing was performed with Chart v5.0 software and heart rate variability (HRV) analysis was done with the HRV plug-in for Chart v5.0 (AD Instruments). This software detects R waves from all ECG leads after passing the signals through a filter that eliminates noise and applying an algorithm that detects ECG fiducial points. All R-R interval data were screened on the computer to confirm the sinus origin of the rhythm. We evaluated the ratio of low frequency (LF; 0.4--1.5 Hz) and high frequency (HF; 1.5--4.0 Hz) as a marker of sympathetic activity, and normalized HF (nHF) as a marker of parasympathetic activity to examine the effects of BO treatment \[[@pone.0236547.ref024],[@pone.0236547.ref025]\]. We also evaluated the standard deviation of normal R-R intervals (SDNN), which is a measure of total autonomic instability \[[@pone.0236547.ref024],[@pone.0236547.ref025]\].

![Effects of BO on serum corticosterone levels, LF/HF, nHF, mean HR and HRV.\
**(A)** ECG was recorded for 24 h at 1 day before the BO treatment (Baseline; BO-1day) and at 1, 7 and 14 days after the BO treatment (BO). **(B)** Serum corticosterone level was significantly increased by the BO treatment for 14 days, compared to the control group. \*\**P* \< 0.01 by Student *t*-test **(S3A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(C)** LF/HF, an index of the sympathetic nervous activity, was significantly greater at all time points in the BO group, compared to the baseline. \*\**P* \< 0.01 (BO-1day vs. BO+1day), ^\#\#^*P* \< 0.01 (BO--1day vs. BO+7day), ^§§^*P* \< 0.01 (BO--1day vs. BO+14day) by one-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **(S3B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(D)** nHF, an index of parasympathetic activity, was significantly smaller at all time points in the BO group, compared to the baseline. \*\**P* \< 0.01 (BO-1day vs. BO+1day), ^\#\#^*P* \< 0.01 (BO--1day vs. BO+7day), ^§§^*P* \< 0.01 (BO--1day vs. BO+14day) by one-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **(S3C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(E)** Mean HR was significantly smaller at all time points in the BO group, compared to the baseline. \*\**P* \< 0.01 (BO-1day vs. BO+1day), ^\#\#^*P* \< 0.01 (BO--1day vs. BO+7day), ^§§^*P* \< 0.05 (BO--1day vs. BO+14day) by one-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **(S3D Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(F)** SDNN was significantly greater at all time points in the BO group, compared to the baseline. \*\**P* \< 0.01 (BO-1day vs. BO+1day), ^\#\#^*P* \< 0.01 (BO--1day vs. BO+7day), ^§§^*P* \< 0.05 (BO--1day vs. BO+14day) by one-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **(S4A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(G)** Time course changes in heart rate during 24 h of ECG measurement at 1 day before and 1, 7 and 14 days after BO treatment. \*\**P* \< 0.01 (BO-1day vs. BO+1day), ^\#\#^*P* \< 0.01 (BO--1day vs. BO+7day), ^§§^*P* \< 0.01 (BO--1day vs. BO+14day), ^††^*P* \< 0.01 (BO+1day vs. BO+7day), ^‡‡^*P* \< 0.01 (BO+1day vs. BO+14day) and ^※※^*P* \< 0.01 (BO+7day vs. BO+14day) by two-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **(S4B of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.](pone.0236547.g002){#pone.0236547.g002}

![Effects of BO on fibrosis and apoptosis in the heart.\
**(A)** Representative images of Masson-trichrome-stained sections of cardiac muscle in the Control (*upper left*), BO (*upper right*), Pro (*lower left*) and BO + Pro (*lower right*) groups. **(B)** The area of fibrosis was significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \**P* \< 0.05 or \*\**P* \< 0.01 by one-way repeated-measures ANOVA followed by the Tukey-Kramer *post hoc* test **(S5A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(C)** TUNEL-positive nuclei (black arrows) in representative TUNEL-stained sections were counted in cardiac muscle in the Control (*upper left*), BO (*upper right*), Pro (*lower left*) and BO + Pro (*lower right*) groups. **(D)** The number of TUNEL-positive nuclei was significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer *post hoc* test **(S5B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. Data show means ± SD and scattered dots show individual data.](pone.0236547.g003){#pone.0236547.g003}

Evaluation of fibrosis {#sec007}
----------------------

Cross sections (10 μm) (Control: *n* = 6; BO: *n* = 6; Pro: *n* = 6; BO + Pro: *n* = 6) were cut with a cryostat (CM1900, Leica Microsystems, Nussloch, Germany) at -20°C. The sections were air-dried and fixed with 4% paraformaldehyde (v/v) in 0.1M phosphate-buffered saline (pH 7.5) \[[@pone.0236547.ref022],[@pone.0236547.ref026],[@pone.0236547.ref027]\].

Interstitial fibrosis was evaluated by Masson-trichrome staining using the Accustatin Trichrome Stain Kit (\#HT15-1KT; Sigma) in accordance with the manufacturer's protocol \[[@pone.0236547.ref026],[@pone.0236547.ref027]\]. Interstitial fibrotic regions were quantified using image software analysis (Image J 1.45) of the percentage of blue area in the Masson-trichrome sections \[[@pone.0236547.ref021],[@pone.0236547.ref026],[@pone.0236547.ref027]\].

Evaluation of apoptosis {#sec008}
-----------------------

Apoptosis was determined by terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) staining using the Apoptosis *in situ* Detection Kit (\#293--71501; Wako, Osaka, Japan). TUNEL-positive nuclei per field of view were manually counted in six sections from the four groups (Control; *n* = 6, BO; *n* = 6, Pro; *n* = 6, BO + Pro; *n* = 6) over a microscopic field of 20 x, averaged and expressed as the ratio of TUNEL-positive nuclei (%) \[[@pone.0236547.ref021],[@pone.0236547.ref026]--[@pone.0236547.ref028]\]. Limiting the counting of total nuclei and TUNEL-positive nuclei to areas with a true cross section of myocytes made it possible to selectively count only those nuclei that were clearly located within myocytes.

Western blotting {#sec009}
----------------

Cardiac muscle excised from the mice was homogenized in a Polytron (Kinematica AG, Lucerne, Switzerland) in ice-cold RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA: 25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) without addition of protein inhibitors \[[@pone.0236547.ref029]\], and the homogenate was centrifuged at 13,000 ~X~ *g* for 10 min at 4°C. The supernatant was collected and the protein concentration was measured using a DC protein assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein (5 μg) (Control; *n* = 6, BO; *n* = 6, Pro; *n* = 6, BO + Pro; *n* = 6) were subjected to 12.5% SDS-polyacrylamide gel electrophoresis and blotted onto 0.2 mm PVDF membrane (Millipore, Billerica, MA, USA).

Western blotting was conducted with commercially available antibodies \[[@pone.0236547.ref021],[@pone.0236547.ref028],[@pone.0236547.ref030],[@pone.0236547.ref031]\]. Primary antibodies directed against the following proteins were purchased from the indicated sources: Akt (1:1000, \#9272) \[[@pone.0236547.ref026]\], phospho-Akt (1:1000, Ser-473, \#9721) \[[@pone.0236547.ref026]\], CaMKII (1:1000, \#3362) \[[@pone.0236547.ref032]\], phospho-CaMKII (1:1000, Thr-286, \#3361) \[[@pone.0236547.ref032]\], BAX (1:1000, \#2772) \[[@pone.0236547.ref021]\], LC3 (1:1000, \#12741) \[[@pone.0236547.ref021]\], Bcl-2 (1:1000, \#3498) \[[@pone.0236547.ref028]\], phospho-mTOR (1:1000, Ser-2448, \#5536; Ser-2481, \#2974) \[[@pone.0236547.ref026]\], mTOR (1:1000, \#2972) \[[@pone.0236547.ref026]\] and RIP3 (1:1000, \#95702) \[[@pone.0236547.ref033]\] from Cell Signaling Technology (Boston, MA, USA), p62 (\#PM045) from MBL (Nagoya, Japan), and GAPDH (sc-25778) \[[@pone.0236547.ref026]\] from Santa Cruz Biotechnology (Santa Cruz, CA, USA), phosphorylated phospholamban (PLN) (1:5000, phospho-Ser-16, \#A010-12; 1:1000, phospho-Thr-17, \#A010-13) \[[@pone.0236547.ref021]\] and PLN (1:2000, \#A010-14) \[[@pone.0236547.ref021]\] from Badrilla (Leeds, UK). Horseradish peroxide-conjugated anti-rabbit (1:1000, \#NA934) or anti-mouse IgG (\#NA931) antibodies \[[@pone.0236547.ref026]\] purchased from GB Healthcare were used as secondary antibodies. The primary and secondary antibodies were diluted in Tris-buffered saline (pH 7.6) with 0.1% Tween 20 and 5% bovine serum albumin. Protein oxidation was measured using the OxiSelect^TM^Protein Carbonyl Immunoblot Kit (\#STA-308; Cell Biolabs, Inc. San Diego, CA, USA) according to the manufacturer's instructions \[[@pone.0236547.ref034],[@pone.0236547.ref035]\]. The blots were visualized with enhanced chemiluminescence solution (ECL: Prime Western Blotting Detection Reagent, GE Healthcare, Piscataway, NJ, USA) and scanned with a densitometer (LAS-1000, Fuji Photo Film, Tokyo, Japan). The reason why there are different numbers of samples in different western blotting figures **(Figs [4](#pone.0236547.g004){ref-type="fig"}--[6](#pone.0236547.g006){ref-type="fig"}, S6, S8 and S9 Figs of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** is that we excluded outliers (extremely low or high values, compare to others in the same group).

![Effects of BO on RIP3 and Akt/mTOR signaling in the heart.\
**(A)** Expression of RIP3, a key mediator of necroptosis, was significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \**P* \< 0.05 or \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer *post hoc* test **(S7A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(B)** Akt phosphorylation at Ser 473 was significantly decreased in the BO group, but this decrease was blocked in the BO + Pro group. \**P* \< 0.05 or \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer *post hoc* test **(S7B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(C)** mTOR phosphorylation at Ser 2448, a specific marker of mTORC1 formation, was significantly decreased in the BO group, but this decrease was blocked in the BO + Pro group. \**P* \< 0.05 or \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer *post hoc* test **(S7C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. Data show means ± SD and scattered dots show individual data. Full-size images of immunoblots are presented in [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"} of supporting information.](pone.0236547.g004){#pone.0236547.g004}

![Effects of BO on mTORC2 phosphorylation, LC3 and p62 expression in cardiac muscle.\
**(A)** mTOR phosphorylation at Ser 2481, a specific marker of mTORC2 formation, was significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \**P* \< 0.05 by one-way ANOVA followed by the Tukey-Kramer post hoc test **(S10A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(B)** Expression of LC3-II, an autophagosome marker, was significantly decreased in the BO group, but this decrease was blocked in the BO + Pro group. \*\**P* \< 0.01 by one-way ANOVA followed by Tukey-Kramer *post hoc* test **(S10B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(C)** p62 expression, which correlates inversely with autophagic degradative activity, i.e., autophagic flux, was significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer *post hoc* test **(S10C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. Data show means ± SD and scattered dots show individual data. Full-size images of immunoblots are presented in [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"} of supporting information.](pone.0236547.g005){#pone.0236547.g005}

![Effects of BO on oxidative stress in cardiac muscle.\
**(A)** Representative images of immunohistochemical detection of oxidative DNA damage (8-OHdG) in cardiac muscle in the Control (*upper left*), BO (*upper right*), Pro (*lower left*) and BO + Pro (*lower right*) groups. **(B)** 8-OHdG-positive nuclei was significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer post hoc test **(S11A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. **(C)** Representative SDS-PAGE of oxidized proteins in cardiac muscle homogenate prepared from Control (*lane 1*), BO (*lane 2*), Pro (*lane 3*) and BO + Pro (*lane 4*) groups using the OxiSelect^TM^Protein Carbonyl Immunoblot Kit. **(D)** Oxidized proteins were significantly increased in the BO group, but this increase was blocked in the BO + Pro group. \*\**P* \< 0.01 by one-way ANOVA followed by the Tukey-Kramer post hoc test **(S11B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. Data expressed as means ± SD and scattered dots show individual data.](pone.0236547.g006){#pone.0236547.g006}

Immunostaining {#sec010}
--------------

Oxidative DNA damage in the myocardium was evaluated by immunostaining for 8-hydroxy-2'-deoxyguanosine (8-OHdG) using the Vector M.O.M Immunodetection system (\#PK-2200, Vector Laboratories, Inc. Burlingame, CA, USA) \[[@pone.0236547.ref036],[@pone.0236547.ref037]\]. Cross sections (Control; *n* = 6, BO; *n* = 6, Pro; *n* = 6, BO + Pro; *n* = 6), were cut with a cryostat at -20°C at 10 μm, air-dried and fixed with 4% paraformaldehyde (v/v) in TBS-T for 5 min at room temperature. Antigen retrieval was achieved with 0.1% citrate plus 1% Triton X-100 for 30 min at room temperature, then the sections were washed with TBS-T, incubated with 0.3% horse serum in TBS-T for 1 h at room temperature, and blocked with M.O.M. blocking reagents (Vector Laboratories, Burlingame, CA, USA) overnight at 4°C. For the positive control, sections were incubated with 0.3% H~2~O~2~ in TBS-T before the anti-8-OHdG antibody treatment. The sections were incubated with anti-8-OHdG antibody (8.3 μg/ml in M.O.M. Dilute; clone N45.1 monoclonal antibody; Japan Institute for the Control of Aging, Shizuoka, Japan) overnight at 4°C in a humidified chamber, and then incubated with 0.3% H~2~O~2~ in 0.3% horse serum for 1 h at room temperature to inactivate endogenous peroxidase, rinsed with TBS-T, incubated with anti-mouse IgG in M.O.M. Diluent, and processed with an ABC kit (Vector Laboratories, Inc. Burlingame, CA, USA). We calculated the ratio of 8-OHdG nuclei with oxidative DNA damage (stained dark blown) per total cell numbers.

Method validation {#sec011}
-----------------

The procedures used in this study were similar to those used in our previous work: echocardiography \[[@pone.0236547.ref021],[@pone.0236547.ref038]\], HRV analysis \[[@pone.0236547.ref024],[@pone.0236547.ref025]\], Masson-trichrome staining and TUNEL staining \[[@pone.0236547.ref021],[@pone.0236547.ref026]\], western blotting \[[@pone.0236547.ref022],[@pone.0236547.ref039]\] and immunostaining \[[@pone.0236547.ref022],[@pone.0236547.ref026]\], and each method was validated for reliability and reproducibility for each procedure.

Statistical analysis {#sec012}
--------------------

Data are expressed as means ± SD. Comparison of data was performed using a Student's *t*-test for 2 groups **([Fig 2B](#pone.0236547.g002){ref-type="fig"})**, one-way repeated-measures analysis of variance (ANOVA) followed by the Bonferroni *post hoc* test **([Fig 2C--2F](#pone.0236547.g002){ref-type="fig"})**, two-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test **([Fig 2G](#pone.0236547.g002){ref-type="fig"}, S2A, S2C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** or one-way ANOVA followed by the Tukey-Kramer *post hoc* test for 3 or more groups **(Figs [3B](#pone.0236547.g003){ref-type="fig"}, [3D](#pone.0236547.g003){ref-type="fig"}, [4A--4C](#pone.0236547.g004){ref-type="fig"}, [5A--5C](#pone.0236547.g005){ref-type="fig"}, [6B and 6D](#pone.0236547.g006){ref-type="fig"}, S6A-S6B, S8, S9A-S9B Figs of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"}, [Table 1](#pone.0236547.t001){ref-type="table"})**. Normality assumption was verified using the Shapiro-Wilk test for all data.

10.1371/journal.pone.0236547.t001

###### Heart size and cardiac function.

![](pone.0236547.t001){#pone.0236547.t001g}

                                 Control (n)      Bite opening (n)   Propranolol (n)    Bite opening Propranolol (n)
  ------------------------------ ---------------- ------------------ ------------------ ------------------------------
  **Body weight (mg)**           28 ± 1.7 (6)     25 ± 1.7 (8)       28 ± 1.3 (6)       25 ± 1.0 (10)
  **CMM (mg)**                   133 ± 26.9 (6)   119 ± 15.2 (8)     136 ± 17.2 (6)     123 ± 14.3 (10)
  **CMM/tibia length (mg/mm)**   6.6 ± 1.2 (6)    5.9 ± 0.8 (8)      6.7 ± 0.7 (6)      6.1 ± 0.7 (10)
  **CMM/body weight (mg/g)**     4.8 ± 0.9 (6)    4.7 ± 0.5 (8)      4.9 ± 0.5 (6)      5.0 ± 0.5 (10)
  **LVEDD (mm)**                 4.3 ± 0.3 (10)   4.0 ± 0.3 (7)      4.1 ± 0.2 (5)      4.3 ± 0.2 (7)
  **LVESD (mm)**                 2.8 ± 0.1 (10)   2.8 ± 0.2 (7)      2.9 ± 0.1 (5)      2.9 ± 0.2 (7)
  **LVEF (%)**                   70 ± 2.0 (10)    63 ± 0.9 (7)\*\*   61 ± 1.8 (5)\*\*   69 ± 2.0 (7)
  **%FS**                        35 ± 1.7 (10)    30 ± 0.6 (7)\*\*   28 ± 1.1 (5)\*\*   33 ± 1.5 (7)

Data are mean ± SD, CMM; cardiac muscle mass

LVEDD; left ventricular end-diastolic diameter

LVESD; left ventricular end-systolic diameter

LVEF; Left ventricular ejection fraction

%FS; % fractional shortening

The total sample size of animals required for statistical validity was calculated for an ɑ risk of 0.05 and a statistical power (1-β) of 0.8 \[[@pone.0236547.ref040]\]. Analyses were performed with PASW statistics 18 (SPSS Inc., Chicago, IL, USA) except for the sample size estimation, which was performed by G\*Power version 3.1. (program, concept and design by Franz, Universitat Kiel, Germany; freely available Windows application software) \[[@pone.0236547.ref041]\]. The criterion of significance was taken as *P* \< 0.05.

Results {#sec013}
=======

Effects of BO on body weight {#sec014}
----------------------------

We monitored the BW of the four groups daily **([Fig 1B](#pone.0236547.g001){ref-type="fig"})**. BW of the Control and Pro groups was similar and showed no significant change during the experimental period. Conversely, BW of the BO and BO + Pro groups gradually decreased and reached a minimum at 4 days after the BO treatment in accordance with previous findings \[[@pone.0236547.ref009],[@pone.0236547.ref042]\] **([Fig 1B](#pone.0236547.g001){ref-type="fig"}, S1 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. After that, the BW of the BO and BO + Pro groups gradually increased, but did not reach the preoperative level during the experimental period at 14 days after BO treatment **([Table 1](#pone.0236547.t001){ref-type="table"}, S12A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

Effects of BO on the consumption of food and drinking water {#sec015}
-----------------------------------------------------------

We monitored the daily consumption of pellet food and water per mouse, measured as an average of group-housed mice in each cage (approximately 3), during the 2-week experimental period. Consumption levels of food **(S2A and S2B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** and water **(S2C and S2D Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** in the Control and Pro groups were similar and did not show significant changes during the experimental period. The BO and the BO + Pro groups might have some difficulty eating, and the consumption of food and water was minimum at 1 day after the BO treatment. However, consumption recovered gradually to preoperative levels within 4 days and no significant difference was observed among the four groups at 2 weeks **(S2A and S2B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. Changes in the consumption of water showed a similar tendency to those of food **(S2C and S2D Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

Effects of BO on serum corticosterone levels {#sec016}
--------------------------------------------

Comparison of the levels of serum corticosterone level, a key biomarker for stress \[[@pone.0236547.ref006],[@pone.0236547.ref009]\], in the control and BO mice at 14 days after the BO treatment revealed a significantly increase of approximately 3.6-fold at 14 days after BO treatment (*n* = 5 each) **([Fig 2B](#pone.0236547.g002){ref-type="fig"}, S3A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. These data suggest that the mice are stressed at 14 days after the BO treatment.

Effects of BO on LF/HF and nHF {#sec017}
------------------------------

To evaluate changes in autonomic nervous activity, we carried out HRV analysis and compared the ratio of LF to HF (LF/HF), an index of the sympathetic nervous activity \[[@pone.0236547.ref025]\], at 1 day before (BO-1 day) and at 1 (BO+1 day), 7 (BO+7day) and 14 days (BO+14day) after the BO treatment. LF/HF was significantly greater than baseline at all time points (*P* \< 0.01 by one-way repeated-measures ANOVA followed by Bonferroni *post hoc* test, *n* = 5 each) **([Fig 2C](#pone.0236547.g002){ref-type="fig"}, S3B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. HF power was normalized to account for differences in total power (nHF), and nHF was examined as an index of parasympathetic activity \[[@pone.0236547.ref025]\]. After BO, nHF was significantly decreased from baseline at all time points (*P* \< 0.01 by one-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test, *n* = 5 each) **([Fig 2D](#pone.0236547.g002){ref-type="fig"}, S3C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that sympathetic nerve activity was increased but parasympathetic activity was decreased after BO treatment.

Effects of BO on HR {#sec018}
-------------------

To evaluate changes of HR, we examined the mean **([Fig 2E](#pone.0236547.g002){ref-type="fig"}, S3D Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** and circadian variation of HR **([Fig 2G](#pone.0236547.g002){ref-type="fig"}, S4B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** at 1 day before the BO treatment to obtain the baseline (BO-1day) and at 1 (BO+1 day), 7 (BO+7day) and 14 days (BO+14day) after the BO treatment.

Mean HR was unexpectedly but significantly decreased at 1, 7 and 14 days after the treatment of BO, compared to the baseline (BO-1day vs. BO+1day, *P* = 3.2 x 10^−2^; BO-1day vs BO+7day, *P* = 3.6 x 10^−5^; BO-1day vs. BO+14day, *P* = 3.6 x 10^−2^ by one- way repeated-measures ANOVA followed by the Bonferroni *post hoc* test, *n* = 5 each) **([Fig 2E](#pone.0236547.g002){ref-type="fig"}, S3D Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

We also examined the circadian variation of HR and found that it was also decreased by the BO treatment (BO-1day vs. BO+1day, *P* = 1.6 x 10^−56^; BO-1day vs BO+7day, *P* = 1.2 x 10^−44^; BO-1day vs. BO+14day, *P* = 7.1 x 10^−19^ by two-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test, *n* = 5 each) **([Fig 2G](#pone.0236547.g002){ref-type="fig"}, S4B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that BO treatment alters the control of HR via the autonomic nervous system.

Effects of BO on SDNN {#sec019}
---------------------

Because the above findings indicated a difference in HR regulation after the treatment of BO, we examined SDNN, which is a measure of total autonomic instability \[[@pone.0236547.ref024],[@pone.0236547.ref025]\].

SDNN was significantly increased at all time points after the BO treatment, compared to the baseline (BO-1day vs. BO+1day, *P* = 2.8 x 10^−3^; BO-1day vs BO+7day, *P* = 3.3 x 10^−2^; BO-1day vs. BO+14day, *P* = 3.2 x 10^−2^ by one-way repeated-measures ANOVA followed by the Bonferroni *post hoc* test, *n* = 5 each) **([Fig 2F](#pone.0236547.g002){ref-type="fig"}, S4A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**, suggesting that autonomic control of the HR was altered after the BO treatment.

Effects of BO on heart size and cardiac function {#sec020}
------------------------------------------------

We examined the effects of BO on heart size in terms of CMM (mg), CMM per tibial length ratio (mg/mm) and CMM per body weight ratio (mg/g) **([Table 1](#pone.0236547.t001){ref-type="table"}, S12 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**, and they were similar in all four groups. However, we cannot rule out the possibility that the statistical power was insufficient to detect BO-mediated cardiac hypertrophy as the total sample size in these cases were not sufficient to provide an α risk of 0.05 and statistical power (1-β) of 0.8 **(S12 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

We also conducted echocardiography **([Table 1](#pone.0236547.t001){ref-type="table"}, S13 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** to evaluate cardiac function in terms of left ventricular ejection fraction (LVEF) and fractional shortening (%FS). Both parameters were significantly decreased in the BO and Pro groups compared to the control. However, no significant changes of LVEF and %FS were observed in the BO + Pro group compared to the control. Also, no significant differences of left ventricular end-diastolic (LVEDD) and left ventricular end-systolic diameter (LVESD) were observed, although we cannot rule out the possibility that the statistical power was insufficient to detect BO-mediated effects on LVEDD and LVESD due to the limited total sample sizes **(S13 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that BO treatment decreased cardiac function without altering the weight of cardiac muscle.

Effects of BO on cardiac fibrosis and apoptosis {#sec021}
-----------------------------------------------

We examined the effects of BO treatment on fibrosis in cardiac muscle by means of Masson-trichrome staining **([Fig 3A](#pone.0236547.g003){ref-type="fig"})**. BO treatment significantly increased the area of fibrosis in cardiac muscle (Control (*n* = 6) vs. BO (*n* = 6); 0.9 ± 0.3 vs. 3.1 ± 2.1%, *P* = 1.2 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test). Propranolol alone did not alter the area of fibrosis, but it blocked the BO-induced increase of fibrosis (BO (*n* = 6) vs. BO + Pro (*n* = 6); 3.1 ± 2.1 vs. 1.0 ± 0.3%, *P* = 1.5 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 3B](#pone.0236547.g003){ref-type="fig"}, S5A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

We also examined the effects of BO treatment on myocyte apoptosis in cardiac muscle by means of TUNEL staining **([Fig 3C](#pone.0236547.g003){ref-type="fig"})**. Myocyte apoptosis in cardiac muscle was significantly increased by BO treatment (Control (*n* = 6) vs. BO (*n* = 6); 0.14 ± 0.13 vs. 0.47 ± 0.15%, *P* = 7.9 x 10^−4^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test). Propranolol alone (*n* = 6) had no effect on the number of TUNEL- positive cardiac myocytes, but it blocked the increase of TUNEL-positive cardiac myocytes induced by BO treatment (BO (*n* = 6) vs. BO + Pro (*n* = 6); 0.47 ± 0.15 vs. 0.15 ± 0.10%, *P* = 1.1 x 10^−3^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 3D](#pone.0236547.g003){ref-type="fig"}, S5B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These results indicate that BO-induced cardiac fibrosis and myocyte apoptosis might be mediated, at least in part, through the activation of β-adrenergic receptor (β-AR) signaling. Importantly, BO-induced cardiac fibrosis and myocyte apoptosis were blocked by co-treatment with propranolol.

Bax expression was increased and Bcl-2 expression was decreased in the heart of BO mice {#sec022}
---------------------------------------------------------------------------------------

Expression of Bax, an accelerator of apoptosis, in the heart was significantly increased by BO treatment (Control (*n* = 4) vs. BO (*n* = 5); 100 ± 8.1 vs. 191 ± 51%, *P* = 1.6 x 10^−2^ vs. Control by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) in accordance with the previous study **(S6A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** \[[@pone.0236547.ref043]\]. Propranolol alone had no effect on Bax expression, but blocked the BO-induced increase (BO (*n* = 5) vs. BO + Pro (*n* = 6); 191 ± 51 vs. 118 ± 49%, *P* = 3.6 x 10^−2^ vs. BO by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **(S6A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

We also found that the expression of Bcl-2, a decelerator of apoptosis, in cardiac muscle was significantly decreased by BO treatment (Control (*n* = 4) vs. BO (*n* = 4); 100 ± 19 vs. 55 ± 22%, *P* = 3.5 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) in accordance with the previous study **(S6B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** \[[@pone.0236547.ref043]\]. Propranolol alone had no effect on the Bcl-2 expression, but blocked the BO-induced decrease (BO (*n* = 4) vs. BO + Pro (*n* = 6); 55 ± 22 vs. 94 ± 17%, *P* = 5.0 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **(S6B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

Effects of BO on necroptosis {#sec023}
----------------------------

Programmed necrosis, often referred as necroptosis, occurs in various cardiovascular diseases \[[@pone.0236547.ref044]\], and receptor-interacting protein 3 (RIP3) is a key determinant of necroptosis, in addition to apoptosis and inflammation, in various types of cells, including cardiac myocytes \[[@pone.0236547.ref033]\]. RIP3 expression in the heart was significantly increased in the BO group (Control (*n* = 6) vs. BO (*n* = 6); 100 ± 1.9 vs. 276 ± 126%, *P* = 2.4 x 10^−3^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test), and propranolol blocked this increase (BO (*n* = 6) vs. BO + Pro (*n* = 6); 276 ± 126 vs. 142 ± 44%, *P* = 2.2 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 4A](#pone.0236547.g004){ref-type="fig"}, S7A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

Thus, necroptosis might contribute to the development of cardiac dysfunction following BO treatment through activation of the β-AR signaling pathway.

Effects of BO on CaMKII phosphorylation {#sec024}
---------------------------------------

CaMKII was recently found to be one of the targets of receptor interacting protein 3 kinase (RIP3), which activates CaMKII via phosphorylation and oxidation \[[@pone.0236547.ref045]\]. Notably, sustained activation of CaMKII is recognized to promote heart failure \[[@pone.0236547.ref046],[@pone.0236547.ref047]\]. We thus examined the amounts of phospho-CaMKII (Thr-286) in the heart of BO mice and found that it was significantly increased (Control (*n* = 6) vs. BO (*n* = 6); 100 ± 16 vs. 311 ± 83%, *P* = 8.9 x 10^−5^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) in accordance with the previous study **(S8 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** \[[@pone.0236547.ref043]\]. Propranolol alone had no effect on the amounts of phospho-CaMKII (Thr-286), but propranolol blocked this increase (BO (*n* = 6) vs. BO + Pro (*n* = 6); 311 ± 83 vs. 127 ± 37%, *P* = 4.6 x 10^−4^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **(S8 Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that BO-induced cardiac dysfunction might be mediated, at least in part, via RIP3/CaMKII signaling downstream of β-AR activation.

Effects of BO on PLN phosphorylation {#sec025}
------------------------------------

The importance of PLN regulation of sarcoendoplasmic reticulum calcium transport ATPase (SERCA) function for cardiac muscle health and in disease is well established \[[@pone.0236547.ref021]\]. We thus examined the effects of BO on PLN phosphorylation in cardiac muscle, focusing on Thr-17, which is phosphorylated by CaMKII, and Ser-16, which is phosphorylated by protein kinase A (PKA). Phospho-PLN (Thr-17) and phospho-PLN (Ser-16) were significantly increased in cardiac muscle of BO mice (PLN (Thr-17): Control (*n* = 5) vs. BO (*n* = 4): 100 ± 16 vs. 165 ± 36%, *P* = 3.2 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test; PLN (Ser-16): Control (*n* = 5) vs. BO (*n* = 5): 100 ± 35 vs. 205 ± 57%, *P* = 2.1 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) in accordance with the previous study **(S9A and S9B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})** \[[@pone.0236547.ref043]\]. Propranolol alone had no effect on the amounts of phospho-PLN (Thr-17 and Ser-16), but propranolol blocked both phosphorylations (PLN (Thr-17): BO (*n* = 4) vs. BO + Pro (*n* = 5); 165 ± 36 vs. 57 ± 40%, *P* = 5.6 x 10^−4^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test; PLN (Ser-16): BO (*n* = 5) vs. BO + Pro (*n* = 6); 205 ± 57 vs. 97 ± 45%, *P* = 1,2 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **(S9A and S9B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that BO-induced cardiac fibrosis and apoptosis might be induced, at least in part, through β-AR-mediated activation of PLN phosphorylation on threonine 17, as well as on serine 16.

Effects of BO on Akt/mTORC1 phosphorylation {#sec026}
-------------------------------------------

We then examined the effects of BO on Akt/mTORC1 signaling **([Fig 4B and 4C](#pone.0236547.g004){ref-type="fig"})**, which is known to be cardioprotective in multiple cardiac pathological conditions \[[@pone.0236547.ref048]--[@pone.0236547.ref051]\]. Akt phosphorylation (Ser-473) of cardiac muscle was significantly decreased in the heart of BO mice (Control (*n* = 6) vs. BO (n = 4): 100 ± 15 vs. 70 ± 13%, *P* = 1.0 x 10^−2^ by the Tukey-Kramer *post hoc* test). Propranolol blocked this decrease (BO (*n* = 4) vs. BO + Pro (*n* = 6); 70 ± 13 vs. 103 ± 10%, *P* = 5.1 x 10^−3^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 4B](#pone.0236547.g004){ref-type="fig"}, S7B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

mTOR phosphorylation on serine 2448, a specific marker of mTORC1 formation, was also significantly decreased in the heart of BO mice (Control (*n* = 6) vs. BO (n = 6): 100 ± 8 vs. 64 ± 16%, *P* = 9.8 x 10^−5^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test). Again, propranolol blocked this decrease (BO (*n* = 6) vs. BO + Pro (*n* = 6); 64 ± 16 vs. 93 ± 6%, *P* = 3.8 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 4C](#pone.0236547.g004){ref-type="fig"}, S7C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that BO-mediated cardiac dysfunction might be mediated, at least in part, through the inhibition of Akt/mTORC1 signaling.

Effects of BO on mTORC2 phosphorylation {#sec027}
---------------------------------------

We also found that mTOR phosphorylation at Ser-2481, a specific marker of mTORC2 formation for the cyclic AMP (cAMP)/PKA signaling pathway in skeletal muscle \[[@pone.0236547.ref026],[@pone.0236547.ref052]\], was also significantly increased in the heart of BO mice (Control (*n* = 6) vs. BO (n = 6): 100 ± 14 vs. 326 ± 291%, *P* = 2.6 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 5A](#pone.0236547.g005){ref-type="fig"}, S10A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**. Propranolol blocked this increase (BO (*n* = 6) vs. BO + Pro (*n* = 6); 326 ± 291 vs. 102 ± 44%, *P* = 2.8 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 5A](#pone.0236547.g005){ref-type="fig"}, S10A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These results suggest that the increase of mTORC2 phosphorylation might also be involved in BO-induced cardiac dysfunction.

Effects of BO on autophagic activity {#sec028}
------------------------------------

We next investigated the effects of BO on autophagy in the heart, because the basal level of autophagy is important to maintain physiological muscle homeostasis, and autophagy also plays a role in the response to stress \[[@pone.0236547.ref053]\].

The amount of microtubule-associated protein light chain 3-II (LC3-II), which is correlated with the number of autophagosomes \[[@pone.0236547.ref054]\], was significantly decreased in the heart of BO mice (Control (*n* = 6) vs. BO (*n* = 6): 100 ± 3 vs. 53 ± 11%, *P* = 1.8 x 10^−3^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test). Propranolol blocked this decrease (BO (*n* = 6) vs. BO + Pro (*n* = 6): 53 ± 11 vs. 93 ± 14%, *P* = 1.0 x 10^−2^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 5B](#pone.0236547.g005){ref-type="fig"}, S10B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

Besides LC3, total cellular expression levels of p62 is inversely correlated with the autophagic degradative activity, i.e., autophagic flux. We found that p62 expression was significantly increased in the BO group (Control (*n* = 6) vs. BO (*n* = 6): 100 ± 2 vs. 207 ± 31%, *P* = 3.7 x 10^−6^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test), but this increase was blocked by propranolol (BO (*n* = 6) vs. BO + Pro (*n* = 6): 207 ± 31 vs. 126 ± 34%, *P* = 1.2 x 10^−4^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 5C](#pone.0236547.g005){ref-type="fig"}, S10C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These data suggest that BO decreases not only the number of autophagosomes, but also the autopahgic flux in the heart via activation of β-AR.

Effects of BO on oxidative stress {#sec029}
---------------------------------

RIP3-induced CaMKII phosphorylation triggers opening of the mitochondrial permeability transition pore and myocardial necroptosis, in addition to apoptosis and inflammation, leading to oxidative stress-induced myocardial damage and heart failure \[[@pone.0236547.ref054]\]. We thus evaluated oxidative stress in the myocardium by means of 8-OHdG immunostaining **([Fig 6A and 6B](#pone.0236547.g006){ref-type="fig"})** and western blotting of oxidized proteins **([Fig 6C and 6D](#pone.0236547.g006){ref-type="fig"})**. In order to confirm the validity of the immunostaining for 8-OHdG, we first prepared positive and negative control sections by incubating with (positive control)/without (negative control) 0.3% H~2~O~2~ in TBS-T for 1 h at room temperature before the anti-8-OHdG antibody treatment and confirmed that the 8-OHdG staining procedure used in this study could clearly discriminate 8-OHdG-positive and non-positive nuclei **(S11C Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

The ratio of 8-OHdG-positive/total cells was significantly increased in the BO group (Control (*n* = 6) vs. BO (*n* = 6): 1.9 ± 1.1 vs. 14.1 ± 2.9%, *P* = 3.5 x 10^−11^ by one- way ANOVA followed by the Tukey-Kramer *post hoc* test), and the increase was blocked by propranolol (BO (*n* = 6) vs. BO + Pro (*n* = 6): 15.0 ± 2.9 vs. 2.1 ± 0.8%, *P* = 5.2 x 10^−11^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 6A and 6B](#pone.0236547.g006){ref-type="fig"}, S11A Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

The amount of oxidized proteins, measured using the OxiSelect TM protein kit, was also significantly increased (Control (*n* = 6) vs. BO (*n* = 6): 100 ± 6.2 vs. 383 ± 245%, *P* = 3.8 x 10^−3^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test), and again the increase was blocked by propranolol (BO (*n* = 6) vs. BO + Pro (*n* = 6): 383 ± 245 vs. 96 ± 25%, *P* = 3.4 x 10^−3^ by one-way ANOVA followed by the Tukey-Kramer *post hoc* test) **([Fig 6C and 6D](#pone.0236547.g006){ref-type="fig"}, S11B Fig of [S1 Data](#pone.0236547.s001){ref-type="supplementary-material"})**.

These results indicate that BO treatment increases oxidative stress-induced myocardial damage, which might contribute to the cardiac dysfunction in BO mice.

Discussion {#sec030}
==========

Our aim was to evaluate potential effects of occlusal disharmony on cardiac homeostasis using BO mice, which have been used in research on occlusal disharmony previously by us and other groups \[[@pone.0236547.ref008],[@pone.0236547.ref009],[@pone.0236547.ref015]\]. Our research was motivated by existing knowledge of the impact of psychological and physical stress, and subsequent increase of sympathetic nerve activity, on the development of cardiovascular disease in humans, even though the mechanism remains poorly understood \[[@pone.0236547.ref055],[@pone.0236547.ref056]\]. We first confirmed that BO increases stress by measuring corticosterone levels and altered HR control by the autonomic nervous system in BO mice. Secondary effects on the heart include increases of cardiac fibrosis, cardiac myocyte apoptosis and oxidative stress with decreased cardiac function and altered signal transduction in cardiac muscle.

Although acute sympathetic stimulation is a major mechanism to improve cardiac dysfunction, chronic sympathetic stimulation, as typically seen in heart failure, induces cardiac myocyte apoptosis, which leads to further deterioration of cardiac function and intensification of heart failure \[[@pone.0236547.ref021],[@pone.0236547.ref028],[@pone.0236547.ref030],[@pone.0236547.ref051]\]. Recently, it has been shown that chronic sympathetic stimulation activates not only the cAMP/PKA pathway, but also cAMP/exchange protein directly activated by cAMP (Epac) pathway \[[@pone.0236547.ref057],[@pone.0236547.ref058]\]. More recently, we showed that increased PLN phosphorylation on serine 16, a major target of cAMP/PKA and the cAMP/Epac pathway, and on threonine 17, a major target of the CaMKII pathway leading to enhanced Ca^2+^ leakage from sarcoplastic reticulumn, may cause cardiac dysfunction in responses to various stresses \[[@pone.0236547.ref021]\]. Our current findings, together with the previous studies, indicated that BO-induced cardiac dysfunction might be mediated through the activation of β-AR. Also, BO-induced alteration of cardiac homeostasis was completely blocked by co-treatment with the non-selective β-AR blocker propranolol \[[@pone.0236547.ref059]\].

We also carried out HRV analysis and compared the ratio of LF/HF, an index of the sympathetic nervous activity \[[@pone.0236547.ref025]\], nHF, an index of the parasympathetic nervous activity, and SDNN, which is a measure of total autonomic instability \[[@pone.0236547.ref024],[@pone.0236547.ref025],[@pone.0236547.ref060]\], at 1 day before (baseline) and at 1, 7 and 14 days after BO treatment. The LF/HF ratio was significantly increased and nHF was significantly decreased, compared to the baseline at all time points after BO, as expected, because occlusal disharmony increases stress in humans \[[@pone.0236547.ref061],[@pone.0236547.ref062]\] and in rats \[[@pone.0236547.ref006]\]. However, mean HR was unexpectedly reduced in BO mice, compared to the control baseline. Recently, it has been demonstrated that rats exposed to stress exhibit significantly increased serum corticosterone levels (\> 200 ng/mL from baseline) to the same degree as BO mice, and show decreased HR, compared to the baseline, even if the LF/HF ratio is increased and nHF is decreased, as observed in BO mice \[[@pone.0236547.ref063]\]. SDNN reflects the balance between the sympathetic and parasympathetic inputs to the cardiac pacemaker and thus SDNN is also a measure of total autonomic instability \[[@pone.0236547.ref024],[@pone.0236547.ref025],[@pone.0236547.ref060]\]. We do not completely understand the mechanisms that contribute to the decreased HR after BO treatment. We have previously demonstrated that SDNN and R-R interval are significantly increased under microgravity stress in type 5 adenylyl cyclase (a major cardiac and Gi-inhibitable isoform) null mice, which show loss of parasympathetic restraint \[[@pone.0236547.ref024],[@pone.0236547.ref030]\]. Since behavioral and physiological flexibility to respond to stress depend upon parasympathetic modulation, our results indicated that decreased HR after the BO treatment might be mediated through the altered parasympathetic modulation in the heart of BO mice.

Previous clinical and experimental findings support a major role for activation of the sympathetic nervous system and parasympathetic nervous withdrawal in the genesis of heart failure and in heart failure progression \[[@pone.0236547.ref021],[@pone.0236547.ref028],[@pone.0236547.ref051],[@pone.0236547.ref064],[@pone.0236547.ref065]\]. This autonomic imbalance exerts adverse effects on the heart, blood vessels, and kidneys, resulting in pathological left ventricular remodeling, peripheral vasoconstriction, and salt and water retention, respectively \[[@pone.0236547.ref066],[@pone.0236547.ref067]\]. These observations, along with the success of β-AR blockade in the treatment of heart failure, provide a rationale for therapies that inhibit adrenergic activity, enhance parasympathetic activity, or, preferably, accomplish both, leading to a decreased risk of death as well as hospitalization for cardiovascular causes in patients with heart failure \[[@pone.0236547.ref059],[@pone.0236547.ref067],[@pone.0236547.ref068]\]. This study, together with the previous studies, indicated that occlusal disharmony might cause cardiovascular disease through the disturbances in sympathetic/parasympathetic neural regulation, and β-AR blockade might reduce the risk of occlusal disharmony-mediated cardiovascular diseases.

In conclusion, our results indicate that occlusal disharmony-induced stress leads to cardiac dysfunction through the activation of sympathetic nerve activity, which can be blocked by propranolol. The cardiac dysfunction is mediated by increased PLN phosphorylation at threonine 17 and serine 16, as well as inhibition of Akt/mTOR signaling and autophagic activity, leading to cardiac fibrosis, cardiac myocyte apoptosis, and oxidative stress **([Fig 7](#pone.0236547.g007){ref-type="fig"})**. Consequently, occlusal disharmony might alter cardiac homeostasis through activation of the sympathetic nervous system and reduction of the parasympathetic influence on the heart.

![Schematic illustration of the proposed role of β-AR signaling in cardiac muscle.\
This scheme illustrates the proposed role of β-AR signaling in the heart of BO-treated mice. β-AR signaling is activated by the BO treatment, leading to the activation of CaMKII-mediated PLN phosphorylation (Thr-17), and cAMP/PKA -mediated PLN phosphorylation (Ser-16), but cardioprotective signaling such as Akt and autophagic signaling was decreased by the BO treatment (*left*). On the other hand, co-treatment with propranolol (*right*) protected the heart from BO-induced cardiac dysfunction. CaMKII: calmodulin kinase II, SERCA2a: sarcoendoplasmic reticulumn (SR) calcium transport ATPase.](pone.0236547.g007){#pone.0236547.g007}
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this manuscript, the authors examined the effects of occlusal disharmony on cardiac function in bite-opening mice and tested the effects of propranolol. Differences shown in the results are clear, however, this reviewer has some concerns about description of the manuscript and design of the experiments. More specifically, 24 hours of heart rate monitoring just after 1 day from the treatment does not support that viewpoint that BO induces chronic sympathetic nerve activation even though beta blocker suppresses the all changes induced by the BO treatment.

Running title

Do the author's findings really indicate heart failure in mice?

Method

Page 7 and following. Please indicate number of animals that were used in this study.

Page 8, Line 2. It would be better to include approval number from the internal committee in text, if applicable.

Page 8, Line 4. What timing did the authors perform physiological experiments?

Page 8, Line 5. How many animals and groups were tested?

Page 8, Line 5. Please indicate given dose of isoflurane, e.g. 2% isoflurane in room air, etc.

Page 8, Line 10. How many animals and groups were tested? Please clarify.

Page 8, Line 10. What type of transmitter was used? Did the authors really implant it into "consciousness" mice without any of anesthesia and analgesia?

Page 8, Line 16. Why did the authors decide to record ECG data at 1 day after the BO treatment? Why not 7 days later?

Page 8, Line 17. "HRV" should be specified.

Page 9, Line 6. Please check the sentence.

Page 9, Line 10. What was the method for euthanasia?

Page 13, Line 2. "8-OH-dG"

Page 13, Line 6. If applicable, please indicate what application was used to perform the statistical analysis.

Results

Overall, this section is too wordy, and some sentences can be moved to discussion section.

Page 14, Line 15. Mice were group housed. Was food and water consumption measured as average of 3-4 mice? If so, please indicate in the text.

Page 15, Line 11. Please show time course changes in heart rate during 24 h of ECG measurement (circadian rhythm). Did heart rate increase in BO mice? and did it last for further 14 days? Do the authors think that propranolol treatment affects these changes?

Page 16, Line 7. CA to indicate "cardiac muscle mass" does not make sense.

Page 16, Line 13. Please reconsider this sentence.

Page 16, Line 16. Please explain or discuss why did these changes occur. Do the authors know or have an evidence that acute increase in sympathetic activity decrease ejection fraction in the heart?

Page 16, Line 17. "Beta-AR" should be specified.

Page 18, Line 1. This sentence might be too speculative since the authors used non-selective beta blocker, propranolol.

Discussion

The results were not well discussed in this section. Please discuss what does your data mean here.

Figure1

In figure 1D and 1E, error bars are missing.

After BO, LH/HF decreased toward the baseline level within 48 h from BO treatment. This reviewer guesses this may not be chronic increase in sympathetic nerve activity. Do the authors think that LF/HF returns to normal level or maintained at high level at 7 days and 14 days from the BO treatment?

Reviewer \#2: The paper shows that propranolol changed cardiac fibrosis in a occlusal disharmony model.

This is an interesting study. However, I would like to make some points regarding the manuscript. The article needs to be revised. First, there were no data of any stress markers and heart rate variability (HRV) during 2 weeks in four groups. Second, the paper should be followed by the ARRIVE Guidelines and use the checklist.

TITLE

1\. The present study did not investigate cardiac function but only investigate fibrosis and protein expression at one time. Please revise the title.

ABSTRACT

1\. What is the main outcome in this study? Because there were no data of any stress markers and heart rate variability during 2 weeks in four groups, the authors should re-consider the main outcome and then, revise the abstract and text.

2\. The conclusion is not appropriate because this study did not investigate the orthodontic treatment.

INTRODUCTION

1\. The authors did not investigate the cardiac function as above.

2\. The experimental period was only 2 weeks. It does not fit to "chronic stress". Furthermore, the authors did not investigate the stress in this study.

MATERIALS AND METHODS

1\. The authors should add more detail parts according to the ARRIVE Guidelines and checklist (see above).

2\. There were no comments about killing methods and fixation. This reviewer thought that the authors had used Bouin\'s Fluid because they detected 8-OHdG expression. Please add the details in the text.

3\. Please add the approval number in the text (P8).

4\. Did the authors collect the blood sample? If yes, please investigate the status of stress using blood samples.

5\. Did the authors perform the sample size estimation?

6\. Please add the results of any stress markers and heart rate variability (HRV) during 2 weeks in four groups (see above)

7\. In western blotting, the authors should clarify the dilution and reference of each antibody (P11).

8\. What do the authors mean "after paraffinization with 4% (v/v) paraformaldehyde"? (P12) They should revise the sentence carefully. Second, fixation by 4% (v/v) paraformaldehyde affect the staining for 8-OHdG and it is not recommended. Why did they use 4% (v/v) paraformaldehyde? Third, they have to perform antigen retrieval following the guideline when they use 4% (v/v) paraformaldehyde.

9\. Please add some comments about validity, reliability and reproducibility in each procedure.

10\. Were the all data parametric? Did the authors check it? When the number was three or four, it was too small in t-test.

11\. In the time course analyses (Figure 1 and Supplement), the authors should use two-way ANOVA or other analyses but not t-test or one-way ANOVA.

RESULTS

1\. The results will be changed by new methods.

2\. Please show the original p value but not "P\<0.05" or NS.

3\. The authors should add the data; i.e., BO vs. Pro, BO vs. BO+Pro, and Pro vs. BO+Pro in all figures because they use the Tuckey-Kramer test.

4\. The number of each group in the Table 1 was wrong. Second, please add the full names, BW, BO, and Pro. Furthermore, please add the statistical name. Please revise them.

5\. The Figure 2C was unclear. Please change it.

6\. Why was the number of each group different among figures? Please clarify it in the text.

DISCUSSION

1\. Please revise the Figure 7 to avoid the misleading. The model does not reflect a chronic stress model and the authors did not investigate stress markers and HRV during the 2 weeks among all groups.

2\. Please delete the comments about periodontal disease (P25) and orthodontic treatment (P26) because the authors did not investigate the effects.

3\. Please revise the discussion following the new results or the guideline.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236547.r002

Author response to Decision Letter 0

4 Jun 2020

Reviewer\#1:

In this manuscript, the authors examined the effects of occlusal disharmony on cardiac function in bite-opening mice and tested the effects of propranolol. Differences shown in the results are clear, however, this reviewer has some concerns about description of the manuscript and design of the experiments. More specifically, 24 hours of heart rate monitoring just after 1 day from the treatment does not support that viewpoint that BO induces chronic sympathetic nerve activation even though beta blocker suppresses the all changes induced by the BO treatment.

1\. Running title

1-(1). Do the author's findings really indicate heart failure in mice?

Responses: We modified the running title as follows.

Intraoral mechanical stress and β-adrenergic signaling

2\. Method

2-(1). Page 7 and following. Please indicate number of animals that were used in this study.

Responses: We incorporated the number of groups and animals in each experiment into the methods section of the revised manuscript (Page 7, Line 1-Page 16, Line 8).

2-(2). Page 8, Line 2. It would be better to include approval number from the internal committee in text, if applicable.

Responses: We incorporated the required information in the revised manuscript as shown below (Page 8, Lines 3-4).

The experimental protocol was approved by the Animal Care and Use Committee of Tsurumi University (No. 29A041)

2-(3). Page 8, Line 4. What timing did the authors perform physiological experiments?

Responses: We incorporated the following sentences in the revised manuscript (Page 8, Line 17-Page 9, Line 2).

\-\-- echocardiographic measurements (Control: n = 10, BO: n = 7, Pro: n = 5; BO + Pro: n = 7) were performed by means of ultrasonography (TUS-A300, Toshiba, Tokyo, Japan) at 14 days after the BO treatment \[1\].

2-(4). Page 8, Line 5, How many animals and groups were tested?

Responses: We incorporated the number of groups in the revised manuscript as shown below (Page 7, Lines 9-11).

\-\--were divided into four groups: a normal control group (Control), a BO-only treatment group (BO), a propranolol-only treatment group (Pro) and a BO plus propranolol treatment group (BO + Pro) (Fig 1A).\-\--

We also incorporated the number of animals in each experiment into the methods section, in response to comment 2-(1) from this reviewer (Page 7, Line 1-Page 16, Line 8).

2-(5). Page 8, Line 5. Please indicate given dose of isoflurane, e.g. 2% isoflurane in room air, etc.

Responses: We incorporated the required information in the revised manuscript as shown below (Page 8, Lines 16-17).

Mice were anesthetized via a mask with isoflurane (1.0-1.5% v/v) at room temperature \-\--

2-(6). Page 8, Line 10. How many animals and groups were tested? Please clarify.

Responses: We incorporated the required information in the revised manuscript as shown below (Page 9, Line 17- Page 10, Line 1).

\-\--a transmitter (F20-EET; Data Sciences International, St. Paul, MN, USA) was implanted into the mice (n = 5) at 14 days before the BO treatment.

2-(7)-1). Page 8, Line 10. What types of transmitter was used?

Responses: Please see the response to comment 2-(6) from this reviewer.

2-(7)-2). Did the authors really implant it into "consciousness" mice without any of anesthesia and analgesia?

Responses: We apologize for the error. We incorporated the following sentences in the revised manuscript (Page 9, Lines 15-Page, Line 1).

Mice were anesthetized with intraperitoneal medetomidine (0.03 mg/ml), midazolam (0.4 mg/ml), and butorphanol (0.5 mg/ml). Then, an abdominal midline incision was made on the ventral surface, and a transmitter (F20-EET; Data Sciences International, St. Paul, MN, USA) was implanted into the mice (n = 5) at 14 days before the BO treatment.

2-(8). Page 8, Line 16. Why did the authors decide to record ECG data at 1 day after the BO treatment? Why not 7 days later?

Responses: We recorded ECG data for 24 h at 1 day before the BO treatment to obtain the baseline, and then at 1, 7 and 14 days after the BO treatment in the revised manuscript.

We incorporated the following sentences in the revised manuscript as shown below (Page 10, Lines 5-6).

ECG data were recorded for 24 h at 1 day before the BO treatment to obtain the baseline and at 1, 7 and 14 days after the BO treatment (Fig 2A) \[2,3\].

We also incorporated the above data into the results section (Page 18, Line 12-Page 20, Line 17) and Fig 2C-G of the revised manuscript.

2-(9). Page 8, Line 17. "HRV" should be specified.

Responses: "HRV" is an abbreviation for heart rate variability. We defined this abbreviation in the revised manuscript (Page 10, Line 7-8).

2-(10). Page 9, Line 6. Please check the sentence.

Responses: Thank you. We modified the sentence as shown below in the revised manuscript (Page 10, Lines 14-15).

\-\--as a marker of parasympathetic activity to examine the effects of BO treatment

\[2,3\].

2-(11). What was the method for euthanasia?

Response: We incorporated the following sentences in the revised manuscript with new references (Page 9, Lines 2-4).

After the completion of echocardiographic measurement, mice were anesthetized via a mask with isoflurane (1.0-1.5% v/v) at room temperature and killed by cervical dislocation \[4,5\].

2-(12). Page 13, Line 2. "8-OH-dG"

Response: "8-OHdG" is an abbreviation for 8-hydroxy-2'-deoxyguanosine. We specified this abbreviation in the revised manuscript (Page 14, Line 6).

2-(13). Page 13, Line 6. If applicable, please indicate what application was used to perform the statistical analysis.

Response: We incorporated the required information in the revised manuscript with a new reference as shown below (Page 16, Lines 4-8).

Analyses were performed with PASW statistics 18 (SPSS Inc., Chicago, IL, USA) except for the sample size estimation, which was performed by G\*Power version 3.1. (program, concept and design by Franz, Universitat Kiel, Germany; freely available windows application software) \[6\].

3\. Results

3-(1). Overall, this section is too wordy, and some sentences can be moved to discussion section.

Response: We have made the suggested changes.

3-(2). Page 14, Line 15. Mice were group housed. Was food and water consumption measured as average of 3-4 mice? If so, please indicate in the text.

Response: Yes. We incorporated the following sentences in the revised manuscript (Page 17, Lines 12-14).

\-\--consumption of pellet food and water per mouse, measured as an average of group-housed mice in each cage (approximately 3), during the 2-week experimental period.

3-(3). Page 15, Line 11. Please show time course changes in heart rate during 24 h of ECG measurement (circadian rhythm). Did heart rate increase in BO mice? And did it last for further 14 days? Do the authors think that propranolol treatment affects these changes?

Response: We incorporated the required data in the revised manuscript as shown below (Page 19, Line 8-Page 20, Line 7).

Effects of BO on HR

To evaluate changes of HR, we examined the mean (Fig 2E, Fig S3D) and circadian variation of HR (Fig 2G, Fig S4B) at 1 day before the BO treatment to obtain the baseline (BO-1day) and at 1 (BO+1 day), 7 (BO+7day) and 14 days (BO+14day) after the BO treatment.

Mean HR was unexpectedly but significantly decreased at 1, 7 and 14 days after the treatment of BO, compared to the baseline (BO-1day vs. BO+1day, P = 3.2 x 10-2; BO-1day vs BO+7day, P = 3.6 x 10-5; BO-1day vs. BO+14day, P = 3.6 x 10-2 by one- way repeated-measures ANOVA followed by the Bonferroni post hoc test, n = 5 each) (Fig 2E, Fig S3D).

We also examined the circadian variation of HR and found that it was also decreased by the BO treatment (BO-1day vs. BO+1day, P = 1.6 x 10-56; BO-1day vs BO+7day, P = 1.2 x 10-44; BO-1day vs. BO+14day, P = 7.1 x 10-19 by two-way repeated-measures ANOVA followed by the the Bonferroni post hoc test, n = 5 each) (Fig 2G, Fig S4B).

These data suggest that BO treatment alters the control of HR via the autonomic nervous system.

3-(4). Page 16, Line 7. CA to indicate "cardiac muscle mass" does not make sense.

Response: "Cardiac muscle mass" is abbreviated as CMM in the revised manuscript (Page 9, Lines 6).

3-(5). Page 16, Line 13. Please reconsider this sentence.

Response: We modified the sentences as shown below (Page 21, Line 11-14).

However, no significant changes of LVEF and %FS were observed in the BO + Pro group compared to the control. Also, no significant differences of left ventricular end-diastolic (LVEDD) and left ventricular end-systolic diameter (LVESD) were observed,\-\--

3-(6). Page 16, Line 16. Please explain or discuss why did these changes occur. Do the authors know or have evidence that acute increase in sympathetic activity decrease ejection fraction in the heart?

Response: We modified these sentences and moved them to the discussion section (Page 32, Line 12-Page 33, Line 7).

Although acute sympathetic stimulation is a major mechanism to improve cardiac dysfunction, chronic sympathetic stimulation, as typically seen in heart failure, induces cardiac myocyte apoptosis, which leads to further deterioration of cardiac function and intensification of heart failure \[1,7-9\]. Recently, it has been shown that chronic sympathetic stimulation activates not only the cAMP/PKA pathway, but also cAMP/exchange protein directly activated by cAMP (Epac) pathway \[10,11\]. More recently, we showed that increased PLN phosphorylation on serine 16, a major target of the cAMP/PKA and the cAMP/Epac pathway, and on threonine 17, a major target of the CaMKII pathway leading to enhanced Ca2+ leakage from sarcoplastic reticulumn, may cause cardiac dysfunction in responses to various stresses \[1\]. Our current findings, together with the previous studies, indicated that BO-induced cardiac dysfunction might be mediated through the activation of β-AR. Also, BO-induced alteration of cardiac homeostasis was completely blocked by co-treatment with the non-selective β-AR blocker propranolol \[12\].

3-(7). Page 16, Line 17. "Beta-AR" should be specified.

Response: "Beta-AR" is an abbreviation for β-adrenergic receptor. We added this in the revised manuscript (Page 23, Lines 4-5).

3-(8). Page 18, Line 1. This sentence might be too speculative since the authors used non-selective beta blocker, propranolol.

Response: We modified the sentences as shown below (Page 23, Lines 3-6).

These results indicate that BO-induced cardiac fibrosis and myocyte apoptosis might be mediated, at least in part, through the activation of β-adrenergic receptor (β-AR) signaling. Importantly, BO-induced cardiac fibrosis and myocyte apoptosis were blocked by co-treatment with propranolol.

4\. Discussion

4-(1). The results were not well discussed in this section. Please discuss what does your data mean here.

Response: We modified the discussion to make it clear, as suggested (Page 32, Line 1-Page 35, Line 14).

5\. Figure

5-(1). In Figure 1D and 1E, error bar are missing.

Response: Regarding the HRV analysis, we increased the experimental number (n = 5) and followed the response for a 2-week period as shown in Fig 2C-G in the revised manuscript.

5-(2). After BO, LH/HF decreased toward the baseline level within 48 h from BO treatment. This reviewer guesses this may not be chronic increase in sympathetic nerve activity. Do the authors think that LF/HF returns to normal level or maintained at high level at 7 days and 14 days from the BO treatment?

Response: BO treatment increased the LF/HF by approximately 4-fold at 1 day after the BO treatment, and the LF/HF remained unchanged at 14 days.

We incorporated the following sentences in the revised manuscript as shown below (Page 18, Line 12-Page 20, Line 7).

Effects of BO on LF/HF and nHF

To evaluate changes in autonomic nervous activity, we carried out HRV analysis and compared the ratio of LF to HF (LF/HF), an index of the sympathetic nervous activity \[3\], at 1 day before (BO-1 day) and at 1 (BO+1 day), 7 (BO+7day) and 14 days (BO+14day) after BO treatment. LF/HF was significantly greater than baseline at all time points (P \< 0.01 by one-way repeated-measures ANOVA followed by the Bonferroni post hoc test, n = 5 each) (Fig 2C, Fig S3B). HF power was normalized to account for differences in total time power (nHF), and nHF was examined as an index of parasympathetic activity \[3\]. After BO, nHF was significantly decreased from baseline at all time points (P \< 0.01 by one-way repeated-measures ANOVA followed by the Bonferroni post hoc test, n = 5 each) (Fig 2D, Fig S3C).

These data suggest that sympathetic nerve activity was increased but parasympathetic activity was decreased after BO treatment.

Reviewer \#2:

This paper shows that propranolol changes cardiac fibrosis in an occlusal disharmony model. This is an interesting study. However, I would like to make some points regarding the manuscript. The article needs to be revised. First, there were no data of any stress markers and heart rate variability (HRV) during 2 weeks in four groups. Second, the paper should be followed by the ARRIVE GUIDELINES and use the checklist.

1\. Title

1-(1). The present study did not investigate cardiac function but only investigate fibrosis and protein expression at one time. Please revise the title.

Response: We modified the title as follows.

Effects of occlusal disharmony on cardiac homeostasis in mice

2\. Abstract

2-(1). What is the main outcome in this study? Because there were no data of any stress markers and heart rate variability during 2 weeks in four groups, the authors should re-consider the main outcome and then, revise the abstract and text.

Response: We appreciate the suggestion. In the revised manuscript, we examined serum corticosterone level, a key biomarker for stress, at baseline and 14 days after the BO treatment in the revised manuscript \[13\]. We also recorded ECG data for 24 h at 1 day before the BO treatment to obtain the baseline and at 1, 7 and 14 days after the BO treatment, and performed HRV analysis all time points in the revised manuscript in order to respond comments 3-(3) and 5-(2) of reviewer-1.

We have not incorporated HRV analysis of the four groups as this reviewer suggested, as we could not complete the work within the timeframe for PLoS One revision. However, we are currently working another project that includes the HRV analysis of BO mice with/without co-treatment with β-blocker, and we hope to publish this in due course.

We revised the abstract accordingly (Page 3, Line 1-Page 4, Line 4). In addition we revised the text by incorporating the following sentences in the methods and results of the revised manuscript, as the reviewer suggested.

1\) Page 8, Lines 6-13 (methods)

Serum corticosterone measurements

The serum was separated from blood samples collected from the heart of the control (n = 5) and BO mice (n = 5) under anesthesia for 14 days after the BO treatment. Each blood sampling procedure was completed within 30 s from the time of contact with the mouse. The separated serum samples were frozen at -80ºC until measurement. The serum corticosterone levels were determined using a Corticosterone HS EIA kit (\#AC-15F1; Immunodiagnostic Systems Ltd., Tyne & Wear, UK), according to the manufacturer's instructions.

2\) Page 18, Lines 5-10 (results)

Effects of BO on serum corticosterone levels

Comparison of the levels of serum corticosterone level, a key biomarker for stress \[14,15\], in the control and BO mice at 14 days after the BO treatment revealed a significantly increase of approximately 3.6-fold at 14 days after BO treatment (n = 5 each) (Fig 2B, Fig S3A). These data suggest that the mice are stressed at 14 days after the BO treatment.

2-(2). The conclusion is not appropriate because this study did not investigate the orthodontic treatment.

Response: We agree and have modified the conclusion in the abstract as shown below.

Page 4, Lines 3-5 (abstract)

These data suggest that occlusal disharmony might affect cardiac homeostasis via alteration of the autonomic nervous system.

3\. Introduction

3-(1). The authors did not investigate the cardiac function as above.

Response: We modified the sentences as follows (Page 6, Lines 10-13).

Therefore, the aim of this study was to examine the effects of occlusal disharmony on stress markers, heart rate (HR) control via the autonomic nervous system, systolic cardiac function, histology and signal transduction in the heart, using bite-opening (BO) mice, which have previously been used in research on occlusal disharmony \[14,16,17\].

3-(2). The experimental period was only two weeks. It does not fit to "chronic stress". Furthermore, the authors did not investigate the stress in this study.

Response: We agree. We replaced the term "chronic stress" with "stress" in the revised manuscript. As mentioned above, we examined the effects of BO on serum corticosterone level and found that it was significantly increased by approximately 3.6-fold at 14 days after BO treatment (n = 5 each), confirming that the mice are stressed (Fig 2B).　

4\. Materials and Method

4-(1). The authors should add more detail parts according to the ARRIVE GUIDELINEs and checklist (see above).

Response: We incorporated the following sentences in the revised manuscript (Page 7, Line 18-Page 8, Line 4).

All animal experiments complied with the ARRIVE guidelines \[18\] and were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals \[19\] and institutional guidelines. The experimental protocol was approved by the Animal Care and Use Committee of Tsurumi University (No. 29A041).

4-(2). There were no comments about killing methods and fixation. This reviewer thought that the authors had used Bouin's Fluid because they detected 8-OHdG expression. Please add the details in the text.

Response: Regarding the killing method, please see the response to comment 2-(11) from reviewer-1.

We did not use Bouin's Fluid. For fixation, we used 4% paraformaldehyde as in the previous study \[20\]. In order to confirm the validity of the immunostaining for 8-OHdG, we prepared positive and negative control sections by incubating with (positive control)/without (negative control) 0.3% H2O2 in TBS-T for 1 h at room temperature after the antigen retrieval, as described below. We confirmed that the 8-OHdG staining procedure can clearly discriminate 8-OHdG-positive and non-positive nuclei (Fig S9C).

We described the method of 8-OHdG staining in the revised manuscript as follows.

1\) Page 14, Line 4-Page 15, Line 5 (method)

Immunostaining

Oxidative DNA damage in the myocardium was evaluated by immunostaining for 8-hydroxy-2'-deoxyguanosine (8-OHdG) using the Vector M.O.M Immunodetection system (\#PK-2200, Vector Laboratories, Inc. Burlingame, CA, USA) \[20,21\]. Cross sections (Control; n = 6, BO; n = 6, Pro; n = 6, BO + Pro; n = 6), were cut with a cryostat at -20ºC at 10 μm, air-dried and fixed with 4% paraformaldehyde (v/v) in TBS-T for 5 min at room temperature. Antigen retrieval was achieved with 0.1% citrate plus 1% Triton X-100 for 30 min at room temperature, then the sections were washed with TBS-T, incubated with 0.3% horse serum in TBS-T for 1 h at room temperature, and blocked with M.O.M. blocking reagents (Vector Laboratories, Burlingame, CA, USA) overnight at 4ºC. For the positive control, sections were incubated with 0.3% H2O2 in TBS-T before the anti-8-OHdG antibody treatment (8.3 μg/ml in M.O.M. Dilute; clone N45.1 monoclonal antibody; Japan Institute for the Control of Aging, Shizuoka, Japan) overnight at 4ºC in a humidified chamber, and then incubated with 0.3% H2O2 in 0.3% horse serum for 1 h at room temperature to inactivate endogenous peroxidase, rinsed with TBS-T, incubated with anti-mouse IgG in M.O.M. Diluent, and processed with an ABC kit (Vector Laboratories, Inc. Burlingame, CA, USA). We calculated the ratio of 8-OHdG nuclei with oxidative DNA damage (stained dark blown) per total cell numbers

2\) Page 30, Lines 2-7 (results)

In order to confirm the validity of the immunostaining for 8-OHdG, we first prepared positive and negative control section by incubating with (positive control)/without (negative control) 0.3% H2O2 in TBS-T for 1 h at room temperature before the anti-8-OHdG antibody treatment and confirmed that the 8-OHdG staining procedure used in this study could clearly discriminate 8-OHdG-positive and non-positive nuclei (Fig S9C).

4-(3). Please add the approval number in the text (P8).

Response: Done as requested.

4-(4). Did the authors collect the blood sample? If yes, please investigate the status of stress using blood sample.

Response: We did not collect blood samples for the four groups. However, to respond to this reviewer, we prepared control (n = 5) and BO-treated mice (n = 5), harvested the blood samples at 2 weeks, and examined serum corticosterone level, as a biomarker for stress \[13\], as mentioned above. Please see the response to comment 2-(1) from reviewer-2.

4-(5). Did the authors perform the sample size estimation?

Response: We calculated the total sample size of animals required for an ɑ risk of 0.05 and a statistical power (1-β) of 0.8 \[22\] by means of G\*Power version 3.1. (program, concept and design by Franz, Universitat Kiel, Germany; freely available Windows application software) \[6\]. We incorporated the total sample size of all data in the revised manuscript (see Supplementary figures).

However, the total sample sizes required for the statistical analysis of cardiac muscle mass (CMM) (total sample size = 72), CMM/tibia (total sample size = 80), CMM/body weight (total sample size n=196), LVEDD (total sample size = 32) and LVESD (total sample size = 120) were insufficient (Fig S10-S11). We could not prepare enough mice to perform the additional experiments necessary to improve the statistical power within a reasonable timeframe. Instead, we have incorporated a comment on this issue as a study limitation in the revised manuscript as shown below.

1\) Page 16, Lines 3-4 (method)

The total sample size of animals required for statistical validity was calculated for an ɑ risk of 0.05 and a statistical power (1-β) of 0.8 \[22\].

2\) Page 21, Lines 2-6 (result)

We examined the effects of BO on heart size in terms of CMM (mg), CMM per tibial length ratio (mg/mm) and CMM per body weight ratio (mg/g) (Table 1, Fig S10), and they were similar in all four groups. However, we cannot rule out the possibility that the statistical power was insufficient to detect BO-mediated cardiac hypertrophy as the total sample sizes in these cases were insufficient to provide an ɑ risk of 0.05 and a statistical power (1-β) of 0.8 (Fig S10).

3\) Page 21, Lines 12-17

\-\--no significant differences of left ventricular end-diastolic (LVEDD) and left ventricular end-systolic diameter (LVESD) were observed, although we cannot rule out the possibility that the statistical power was insufficient to detect BO-mediated effects on LVEDD and LVESD due to the limited total sample sizes (Fig S11).

4-(6). Please add the results of any stress markers and heart rate variability (HRV) during 2 weeks in four groups (see above).

Response: Please see the response to comment 2-(1) from reviewer-2 (stress markers) and comment 2-(8) from reviewer-1 (HRV).

4-(7). In western blotting, the authors should clarify the dilution and reference of each antibody (p11).

Response: We incorporated the required information in the revised manuscript (Page 12, Line 15-Page 13, Line 10) with new references.

4-(8)-1). What do the authors mean "after paraffinization with 4% (v/v) paraformaldehyde"? (p12). They should revise the sentence carefully.

Response: We apologize. "Paraffinization" should have been "fixation".

Please see the response to the comment 4-(2) from reviewer-2.

4-(8)-2). Second, fixation by 4% (v/v) paraformaldehyde affect the staining for 8-OHdG and it is not recommended. Why did they use 4% (v/v) paraformaldehyde?

Response: Please see the responses to comment 4-(2) from reviewer-2.

4-(8)-3). Third, they have to perform antigen retrieval following the guideline when they use 4% (v/v) paraformaldehyde.

Response: Please see the responses to the criticism 4-(2) from the reviewer-2.

4-(9). Please add some comments about validity, reliability and reproducibility in each procedure.

Response: Thank you for this suggestion. The procedures used in this study were similar to those used in our previous work: echocardiography \[1,23\], HRV analysis \[2,3\], Masson-trichrome staining and TUNEL staining \[1,24\], western blotting \[4,25\] and immunostaining \[4,24\], and each method was validated for reliability and reproducibility for each procedure.

We incorporated the following sentences in the method section of the revised manuscript as shown below (Page 15, Lines 7-11).

Method validation

The procedures used in this study were similar to those used in our previous work: echocardiography \[1,23\], HRV analysis \[2,3\], Masson-trichrome staining and TUNEL staining \[1,24\], western blotting \[4,25\] and immunostaining \[4,24\], and each method was validated for reliability and reproducibility for each procedure.

4-(10). Were the all data parametric? Did the author check it? When the number was three or four, it was too small in t-test.

Response: Normality assumption was verified using the Shapiro-Wilk test for all data in the revised manuscript. We incorporated the following sentences in the method section of the revised manuscript (Page 16, Lines 1-2).

Normality assumption was verified using the Shapiro-Wilk test for all data.

5\. Results.

5-(1). The results will be changed by new methods.

Response: 1) We recorded ECG data for 24 h at 1 day before the BO treatment to obtain the baseline and at 1, 7 and 14 days after the BO treatment in the revised manuscript.

We carried out HRV analyses at all time points and incorporated them in the revised manuscript (Page 18, Line 12-Page 20, Line 17).

2\) We examined serum corticosterone level, a biomarker for stress, at baseline and 14 days after the BO treatment in the revised manuscript (Page 8, Lines 6-13).

3\) We asked Dr. Amitani, a statistics expert and co-author in the revised manuscript, to support us in re-analyzing all of the data. The revised statistics analysis has been added to the revised manuscript (Page 15, Line 13-Page 16, Line 8 and supplementary data).

5-(2). Please show the original p value but not "P\<0.05" or NS

Response: We incorporated the original p value in the results section of the revised manuscript. We also incorporated the original p value for all data in the supplementary data file.

5-(3). The authors should add the data; i.e., BO vs. Pro, BO vs. BO+Pro, and Pro vs. BO+Pro in all figures because they use the tuckey-Kramer test.

Response: We incorporated the required information (BO vs. Pro, BO vs. BO + Pro, and Pro vs. BO + Pro) in all figures of the revised manuscript.

5-(4). The number of each group in the Table 1 was wrong.

Second, please add the full names, BW, BO, and Pro.

Furthermore, please add the statistical name. Please revise them.

Response: Thank you. We have carefully checked and corrected Table 1, as the reviewer suggested.

5-(5). The Figure 2C was unclear. Please change it.

Response: Thank you. We replaced it with a better one.

5-(6). Why was the number of each group different among figures? Please clarify it in the text.

Response: We incorporated the number of groups and animals used in each experiment into the methods section of the revised manuscript (Page 7, Line 1-Page 16, Line 8) in response to comment 2-(1) from reviewer-1. For western blotting, we prepared crude protein homogenate from cardiac muscle excised from six mice of each group. However, we excluded outlying mice with extremely low or high values, compared to others of the same groups, from the analysis. This is why the n number varies in western blotting figures (Fig 4-6).

We incorporated the following sentences in the method section of the revised manuscript.

1\) Page 12, Lines 11-14

Equal amounts of protein (5 μg) (Control; n = 6, BO; n = 6, Pro; n = 6, BO + Pro; n = 6) were subjected to 12.5 % SDS-polyacrylamide gel electrophoresis and blotted onto 0.2 mm PVDF membrane (Millipore, Billerica, MA, USA).

2\) Page 13, Lines 17-Page 14, Line 2

The reason why there are different numbers of samples in different western blotting figures (Fig 4-6) is that we excluded outliers (extremely low or high values, compared to others in the same group).

6\. Discussion

6-(1). Please revise the Figure 7 to avoid the misleading. The model does not a chronic stress model and the authors did not investigate stress markers and HRV during the 2 weeks among all groups.

Response: We revised Figure 8 (Figure 7 in the original version) in line with the reviewer's comments.

6-(2). Please delete the comments about periodontal disease (p25) and orthodontic treatment (p26) because the authors did not investigate the effects.

Response: We deleted these comments as the reviewer suggested.

6-(3). Please revise the discussion following the new results or the guideline.

Response: We revised the discussion to take account of new results as the reviewer suggested.
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Dear Dr. Okumura,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Importantly, this editor, who participated as a reviewer for the initial evaluation of this manuscript, found a critical issue regarding duplicate submission.

A concept of the study has been already described in an original article from the same authors (Yagisawa et al. Circ Cont. 2020). Moreover, parts of western blotting results, especially some bands for control and BO groups seem to be a part of the same membrane shown in the previously published article. (ratio of CaMKII is also weird. \~1200%(previous) vs \~300%(current) in BO group.) I understand that the published article was written in non-English language, however the article has an English abstract and is open-access so anyone can see the figures.

Although the reviewer is favorable to accept the manuscript after some minor revisions (see below), I strongly recommend the authors to disclose the use of previously published data in the revised manuscript (this probably may not fit to the PLOS ONE's publication criteria), or significantly change the manuscript with great care for handling raw data, at least without showing the membrane and images, which were already presented elsewhere.

I would be willing to reconsider this manuscript after it has undergone a major revision.

Please submit your revised manuscript by Aug 07 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Takashi Sonobe, Ph.D.

Academic Editor
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\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The paper was overall improved. However, there are some issues. The paper should be revised.

TITLE

The authors used homeostasis, but it is not appropriate and not concrete. For example, "Effects of occlusal disharmony on cardiac fibrosis, myocyte apoptosis and myocyte oxidative DNA damage in mice".

Please add the timing of serum corticosterone measurements and/or collection. The collection should be in the morning.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]
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Author response to Decision Letter 1

7 Jul 2020

Reviewer \#2: The paper was overall improved. However, there are some issues. The paper should be revised.

TITLE

The papers used homeostasis, but it is not appropriate and not concrete. For example, "Effects of occlusal disharmony on cardiac fibrosis, myocyte apoptosis and myocyte oxidative DNA damage in mice".

Response:

We modified the title as the reviewer suggested.

Please add the timing of serum corticosterone measurements and/or collection. The collection should be in the morning.

Response:

We added the following sentences in the revised manuscript with a new reference (Page 8, Lines 9-10).

Blood sampling was done in the morning (9:00-10:00AM) and the procedure was completed within 30 s from the time of contact with the mouse \[1\].

Editor: \-\-- I strongly recommend the authors to \-\-\--disclose the use of previously published data in the manuscript\-\--, or significantly change the manuscript with great care for handling raw data, at least without showing the membrane and images, \-\--

Response:

We sincerely apologize for omitting to mention our previous paper written in Japanese (Circ Cont 2020). Although we had described the BO-promoted increase of Bax/Bcl-2 ratio, CaMKII phosphorylation (Thr-286) and PLN phosphorylation (Ser-16, Thr-17) in that paper (Circ Cont 2020), it did not describe the effects of propranolol on the BO-promoted increase of these molecules, which are critical for the present manuscript. Accordingly, we adopted your second suggestion to avoid duplication, and have modified Fig 4A, Fig 4B, Fig 4D, Fig 5A and Fig 5B in the original version and incorporated the modified figures in the revised manuscript as Fig S6, Fig S8 and Fig S9. Thus, the revised manuscript no longer duplicates material from the previous paper. We apologize for having failed to spot this before.

We also modified parts in the results section as shown below.

1\) Page 23, Lines 10-16

Expression of Bax, an accelerator of apoptosis, in the heart was significantly increased by BO treatment \-\-- in accordance with the previous study (Fig S6A) \[2\]. Propranolol alone had no effect on Bax expression, but blocked the BO-induced increase\-\-- (Fig S6A).

2\) Page 23, Line 17-Page 24, Line 5

We also found that the expression of Bcl-2, a decelerator of apoptosis, in cardiac muscle was significantly decreased by BO treatment (Control (n = 4) vs. BO (n = 4); 100 ± 19 vs. 55 ± 22 %, P = 3.5 x 10-2 by one-way ANOVA followed by the Tukey-Kramer post hoc test) in accordance with the previous study (Fig S6B) \[2\]. Propranolol alone had no effect on the Bcl-2 expression, but blocked the BO-induced decrease \-\-- (Fig S6B).

3\) Page 25, Lines 6-12

We thus examined the amounts of phospho-CaMKII (Thr-286) in the heart of BO mice and found that it was significantly increased \-\-- in accordance with the previous study (Fig S8) \[2\]. Propranolol alone had no effect on the amounts of phospho-CaMKII (Thr-286), but propranolol blocked this increase \-\-- (Fig S8).

4\) Page 26, Lines 3-12

Phospho-PLN (Thr-17) and phospho-PLN (Ser-16) were significantly increased in cardiac muscle of BO mice\-\-- in accordance with the previous study (Fig S9A and S9B) \[2\]. Propranolol alone had no effect on the amounts of phospho-PLN (Thr-17 and Ser-16), but propranolol blocked both phosphorylations\-\-- (Fig S9A and S9B).
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